Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)".

MLA

Celio, Luigi, et al. “Comment on ‘Dexamethasone-Sparing on Days 2-4 with Combined Palonosteron, Neurokinin-1 Receptor Antagonist, and Olanzapine in Cisplatin: A Randomized Phase III Trial (SPARED Trial).’” British Journal of Cancer, vol. 130, no. 6, Apr. 2024, pp. 895–96. EBSCOhost, https://doi.org/10.1038/s41416-024-02611-z.

APA

Celio, L., Antonuzzo, A., & Aapro, M. S. (2024). Comment on “Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).” British Journal of Cancer, 130(6), 895–896. https://doi.org/10.1038/s41416-024-02611-z

Chicago

Celio, Luigi, Andrea Antonuzzo, and Matti S Aapro. 2024. “Comment on ‘Dexamethasone-Sparing on Days 2-4 with Combined Palonosteron, Neurokinin-1 Receptor Antagonist, and Olanzapine in Cisplatin: A Randomized Phase III Trial (SPARED Trial).’” British Journal of Cancer 130 (6): 895–96. doi:10.1038/s41416-024-02611-z.